 CAMBRIDGE, Mass.--BUSINESS WIRE--Magenta Therapeutics Nasdaq: MGTA, a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced positive preliminary results from its Phase 2 clinical trial of MGTA-145 plus plerixafor in patients with multiple myeloma, which were accepted for presentation at the European Hematology Association EHA Congress, to be held virtually June 9-17, 2021. Magenta also provide 